Literature DB >> 21880636

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes.

Felicitas Thol1, Claudia Winschel, Andrea Lüdeking, Haiyang Yun, Inna Friesen, Frederik Damm, Katharina Wagner, Jürgen Krauter, Michael Heuser, Arnold Ganser.   

Abstract

Gene mutations and epigenetic changes have been shown to play significant roles in the pathogenesis of myelodysplastic syndromes. Recently, mutations in DNMT3A were identified in 22.1% of patients with acute myeloid leukemia. In this study, we analyzed the frequency and clinical impact of DNMT3A mutations in a cohort of 193 patients with myelodysplastic syndromes. Mutations in DNMT3A were found in 2.6% of patients. The majority of mutations were heterozygous missense mutations affecting codon R882. Patients with DNMT3A mutations were found to have a higher rate of transformation to acute myeloid leukemia. When assessing the global methylation levels in patients with mutated versus unmutated DNMT3A and healthy controls no difference in global DNA methylation levels between the two groups was seen. Our data show that in patients with myelodysplastic syndromes, DNMT3A mutations occur at a low frequency and may be a risk factor for leukemia progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880636      PMCID: PMC3232272          DOI: 10.3324/haematol.2011.045559

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  16 in total

1.  DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction.

Authors:  Ann-Marie Bröske; Lena Vockentanz; Shabnam Kharazi; Matthew R Huska; Elena Mancini; Marina Scheller; Christiane Kuhl; Andreas Enns; Marco Prinz; Rudolf Jaenisch; Claus Nerlov; Achim Leutz; Miguel A Andrade-Navarro; Sten Eirik W Jacobsen; Frank Rosenbauer
Journal:  Nat Genet       Date:  2009-10-04       Impact factor: 38.330

2.  Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

Authors:  Felicitas Thol; Frederik Damm; Andrea Lüdeking; Claudia Winschel; Katharina Wagner; Michael Morgan; Haiyang Yun; Gudrun Göhring; Brigitte Schlegelberger; Dieter Hoelzer; Michael Lübbert; Lothar Kanz; Walter Fiedler; Hartmut Kirchner; Gerhard Heil; Jürgen Krauter; Arnold Ganser; Michael Heuser
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

3.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Authors:  Katharina Wagner; Frederik Damm; Gudrun Göhring; Kerstin Görlich; Michael Heuser; Irina Schäfer; Oliver Ottmann; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna A Raghavachar; Walter Fiedler; Hartmut H Kirchner; Wolfram Brugger; Manuela Zucknick; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Jürgen Krauter
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

4.  Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.

Authors:  W K Hofmann; A Ganser; G Seipelt; O G Ottmann; C Zander; G Geissler; K Hoffmann; K Höffken; J T Fischer; G Isele; D Hoelzer
Journal:  Ann Hematol       Date:  1999-03       Impact factor: 3.673

5.  IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Authors:  Felicitas Thol; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Frederik Damm; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Arnold Ganser; Michael Heuser
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.

Authors:  M Stadler; U Germing; K-O Kliche; K M Josten; R Kuse; W-K Hofmann; H Schrezenmeier; J Novotny; O Anders; H Eimermacher; W Verbeek; H-H Kreipe; H Heimpel; C Aul; A Ganser
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

8.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

Authors:  Ying Jiang; Andrew Dunbar; Lukasz P Gondek; Sanjay Mohan; Manjot Rataul; Christine O'Keefe; Mikkael Sekeres; Yogen Saunthararajah; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113

9.  DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

Authors:  Lanlan Shen; Hagop Kantarjian; Yi Guo; E Lin; Jianqin Shan; Xuelin Huang; Donald Berry; Saira Ahmed; Wei Zhu; Sherry Pierce; Yutaka Kondo; Yasuhiro Oki; Jaroslav Jelinek; Hussain Saba; Eli Estey; Jean-Pierre J Issa
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

10.  Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Authors:  Felicitas Thol; Frederik Damm; Katharina Wagner; Gudrun Göhring; Brigitte Schlegelberger; Dieter Hoelzer; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna Raghavachar; Walter Fiedler; Hartmut Kirchner; Gerhard Heil; Michael Heuser; Jürgen Krauter; Arnold Ganser
Journal:  Blood       Date:  2010-04-26       Impact factor: 25.476

View more
  25 in total

Review 1.  Epigenetics in myelodysplastic syndromes.

Authors:  Michael Heuser; Haiyang Yun; Felicitas Thol
Journal:  Semin Cancer Biol       Date:  2017-08-02       Impact factor: 15.707

Review 2.  Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.

Authors:  Tamara K Moyo; Michael R Savona
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 3.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

Review 4.  Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.

Authors:  Guillermo Montalbán Bravo; Elinor Lee; Bryan Merchan; Hagop M Kantarjian; Guillermo García-Manero
Journal:  Br J Haematol       Date:  2014-06-05       Impact factor: 6.998

5.  DNMT3A mutation analysis in adult patients with acute lymphoblastic leukemia.

Authors:  Ya-Nan Liu; Na Zhang; Ying Wu; Li Yang; Xiao-Yi Ding; Jian-Feng Zhou; Min Xiao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

Review 6.  Mutations in epigenetic regulators in myelodysplastic syndromes.

Authors:  Gorica Nikoloski; Bert A van der Reijden; Joop H Jansen
Journal:  Int J Hematol       Date:  2012-01-11       Impact factor: 2.490

7.  [Myelodysplastic syndromes].

Authors:  F Thol; M Heuser; A Ganser
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

8.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

Review 9.  The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?

Authors:  Zaher K Otrock; Ramon V Tiu; Jaroslaw P Maciejewski; Mikkael A Sekeres
Journal:  Expert Rev Hematol       Date:  2013-02       Impact factor: 2.929

Review 10.  Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Authors:  Diamantina Vasilatou; Sotirios G Papageorgiou; George Dimitriadis; Vasiliki Pappa
Journal:  Epigenetics       Date:  2013-05-09       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.